

Benjamin Djulbegovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502117/publications.pdf>

Version: 2024-02-01

397
papers

35,096
citations

16791

66
h-index

4305

179
g-index

426
all docs

426
docs citations

426
times ranked

40347
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-------|-----------|
| 1 | Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane Library, 2022, 2022, CD003039. | 1.5 | 85 |
| 2 | A few panel members dominated guideline development meeting discussions: Social network analysis. Journal of Clinical Epidemiology, 2022, 141, 1-10. | 2.4 | 8 |
| 3 | High quality (certainty) evidence changes less often than low-quality evidence, but the magnitude of effect size does not systematically differ between studies with low versus high-quality evidence. Journal of Evaluation in Clinical Practice, 2022, 28, 353-362. | 0.9 | 5 |
| 4 | Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. Journal of Clinical Epidemiology, 2022, 148, 193-195. | 2.4 | 5 |
| 5 | Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events. Lancet Haematology, the, 2022, 9, e12-e13. | 2.2 | 4 |
| 6 | Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible. Journal of Clinical Epidemiology, 2022, 145, 101-111. | 2.4 | 6 |
| 7 | Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncology Practice, 2021, 17, e257-e265. | 1.4 | 8 |
| 8 | GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes—Study limitations due to censoring of participants with missing data in intervention studies. Journal of Clinical Epidemiology, 2021, 129, 126-137. | 2.4 | 4 |
| 9 | Evidence, values, and masks for control of COVID-19. Journal of Clinical Epidemiology, 2021, 131, 152-157. | 2.4 | 4 |
| 10 | Research synthesis of information theory measures of uncertainty: Meta-analysis of entropy and mutual information of diagnostic tests. Journal of Evaluation in Clinical Practice, 2021, 27, 246-255. | 0.9 | 1 |
| 11 | The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist, 2021, 26, e1418-e1426. | 1.9 | 1 |
| 12 | Ethics of uncertainty. Patient Education and Counseling, 2021, 104, 2628-2634. | 1.0 | 7 |
| 13 | Certainty of evidence and intervention's benefits and harms are key determinants of guidelines™ recommendations. Journal of Clinical Epidemiology, 2021, 136, 1-9. | 2.4 | 14 |
| 14 | GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making. Journal of Clinical Epidemiology, 2021, 129, 138-150. | 2.4 | 81 |
| 15 | Some thoughts on conducting and implementing clinical practice guidelines in a pandemic. Chinese Medical Journal, 2021, 134, 910-912. | 0.9 | 3 |
| 16 | Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. Ca-A Cancer Journal for Clinicians, 2021, 71, 78-92. | 157.7 | 230 |
| 17 | Can we trust strong recommendations based on low quality evidence?. BMJ, The, 2021, 375, n2833. | 3.0 | 12 |
| 18 | Discordant and inappropriate discordant recommendations in consensus and evidence based guidelines: empirical analysis. BMJ, The, 2021, 375, e066045. | 3.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | On Occasion of the 12th "Days of AMNuBiH 2021" and "SWEP 2021" Conferences, Sarajevo, Bosnia and Herzegovina. <i>Acta Informatica Medica</i> , 2021, 29, 295. | 0.5 | 1 |
| 20 | Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 398-406. | 1.7 | 32 |
| 21 | Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1293-1308. | 0.5 | 3 |
| 22 | Evaluation of the U.S. governors' decision when to issue stay-at-home orders. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1347-1351. | 0.9 | 10 |
| 23 | Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. <i>JAMA Oncology</i> , 2020, 6, 1759. | 3.4 | 64 |
| 24 | When are randomized trials unnecessary? A signal detection theory approach to approving new treatments based on non-randomized studies. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 27, 735-742. | 0.9 | 2 |
| 25 | A user guide to the American Society of Hematology clinical practice guidelines. <i>Blood Advances</i> , 2020, 4, 2095-2110. | 2.5 | 14 |
| 26 | Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting: Role of Academic and Hybrid Modeling. <i>Journal of Clinical Medicine</i> , 2020, 9, 1884. | 1.0 | 5 |
| 27 | Evidence-based medicine in times of crisis. <i>Journal of Clinical Epidemiology</i> , 2020, 126, 164-166. | 2.4 | 25 |
| 28 | Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. <i>Journal of Clinical Oncology</i> , 2020, 38, 2558-2569. | 0.8 | 110 |
| 29 | Evidence vs Consensus in Clinical Practice Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 725. | 3.8 | 67 |
| 30 | The importance of randomised vs non-randomised trials. <i>Lancet</i> , The, 2019, 394, 634-635. | 6.3 | 7 |
| 31 | US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials. <i>JAMA Network Open</i> , 2019, 2, e1911111. | 2.8 | 19 |
| 32 | A forgotten β^3 error. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 751-753. | 0.9 | 0 |
| 33 | Failure to place evidence at the centre of quality improvement remains a major barrier for advances in quality improvement. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 369-372. | 0.9 | 11 |
| 34 | Structured decision-making drives guidelines panels' recommendations "for" but not "against" health interventions. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 23-33. | 2.4 | 12 |
| 35 | Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 1336-1351. | 0.8 | 73 |
| 36 | Hematological Malignancies and Arterial Thromboembolism. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 611-624. | 0.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Tolerating uncertainty about conceptual models of uncertainty in health care. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 183-185. | 0.9 | 13 |
| 38 | Statins for Primary Prevention of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 73. | 2.0 | 2 |
| 39 | Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. <i>Annals of Internal Medicine</i> , 2019, 171, 756. | 2.0 | 227 |
| 40 | Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>Blood Advances</i> , 2019, 3, 1197-1210. | 2.5 | 76 |
| 41 | The threshold model revisited. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 186-195. | 0.9 | 33 |
| 42 | A unifying framework for improving health care. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 358-362. | 0.9 | 21 |
| 43 | Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2019, 108, 1-9. | 2.4 | 6 |
| 44 | Precision medicine for individual patients should use population group averages and larger, not smaller, groups. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13031. | 1.7 | 13 |
| 45 | Diagnostic Predictive Model for Diagnosis of Heart Failure after Hematopoietic Cell Transplantation (HCT): Comparison of Traditional Statistical with Machine Learning Modeling. <i>Blood</i> , 2019, 134, 5799-5799. | 0.6 | 1 |
| 46 | Transforming clinical practice guidelines and clinical pathways into fast and frugal decision trees to improve clinical care strategies. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 1247-1254. | 0.9 | 36 |
| 47 | Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval. <i>Journal of Clinical Epidemiology</i> , 2018, 98, 24-32. | 2.4 | 23 |
| 48 | Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 65-71. | 0.9 | 7 |
| 49 | Rational decision making in medicine: Implications for overuse and underuse. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 655-665. | 0.9 | 48 |
| 50 | The Second Mediterranean Seminar on Science Writing, Editing and Publishing (SWEP - 2018), Sarajevo, December 8th, 2018. <i>Acta Informatica Medica</i> , 2018, 26, 284. | 0.5 | 14 |
| 51 | Evidence to Decision framework provides a structured roadmap for making GRADE guidelines recommendations. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 103-112. | 2.4 | 32 |
| 52 | Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S201-S202. | 0.2 | 0 |
| 53 | Bisphosphonates for Patients Diagnosed With Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1483. | 3.8 | 10 |
| 54 | Impact of spinal needle type on postdural puncture headache among women undergoing Cesarean section surgery under spinal anesthesia: A meta-analysis. <i>Journal of Evidence-Based Medicine</i> , 2018, 11, 136-144. | 2.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Elective induction of labor at 39 weeks among nulliparous women: The impact on maternal and neonatal risk. PLoS ONE, 2018, 13, e0193169. | 1.1 | 19 |
| 56 | Heuristic value-based framework for lung cancer decision-making. Oncotarget, 2018, 9, 29877-29891. | 0.8 | 5 |
| 57 | Amino Bisphosphonates Are Associated with Decreased Mortality Compared to Non-Amino Bisphosphonates in the Treatment of Multiple Myeloma. Blood, 2018, 132, 5638-5638. | 0.6 | 0 |
| 58 | How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations. Blood, 2018, 132, 4707-4707. | 0.6 | 0 |
| 59 | The Influence of Activity Roles and Use of a Structured Framework on Developing Hematology Clinical Practice Guidelines. Blood, 2018, 132, 2237-2237. | 0.6 | 0 |
| 60 | Towards theory integration: Threshold model as a link between signal detection theory, fast and frugal trees and evidence accumulation theory. Journal of Evaluation in Clinical Practice, 2017, 23, 49-65. | 0.9 | 19 |
| 61 | Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. Journal of Evaluation in Clinical Practice, 2017, 23, 241-250. | 0.9 | 6 |
| 62 | Monte Carlo decision curve analysis using aggregate data. European Journal of Clinical Investigation, 2017, 47, 176-183. | 1.7 | 5 |
| 63 | Progress in evidence-based medicine: a quarter century on. Lancet, The, 2017, 390, 415-423. | 6.3 | 626 |
| 64 | Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions. Journal of Clinical Epidemiology, 2017, 86, 129-139. | 2.4 | 13 |
| 65 | Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations. European Journal of Cancer, 2017, 75, 159-166. | 1.3 | 11 |
| 66 | Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review. BMJ Open, 2017, 7, e014661. | 0.8 | 26 |
| 67 | What does evidence mean? Most languages translate "evidence" into "proof". Journal of Evaluation in Clinical Practice, 2017, 23, 971-973. | 0.9 | 3 |
| 68 | The predicament of patients with suspected Ebola. The Lancet Global Health, 2017, 5, e657. | 2.9 | 1 |
| 69 | Many faces of rationality: Implications of the great rationality debate for clinical decision-making. Journal of Evaluation in Clinical Practice, 2017, 23, 915-922. | 0.9 | 55 |
| 70 | Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer, 2017, 6, 337-348. | 4.2 | 18 |
| 71 | On evidence-based medicine " Authors' reply. Lancet, The, 2017, 390, 2245-2246. | 6.3 | 1 |
| 72 | Bisphosphonates in multiple myeloma: an updated network meta-analysis. The Cochrane Library, 2017, CD003188. | 1.5 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. The Cochrane Library, 2016, 2016, CD009624. | 1.5 | 38 |
| 74 | NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 389-400. | 2.3 | 62 |
| 75 | Thrombotic thrombocytopenic purpura: gaining knowledge. Lancet Haematology, the, 2016, 3, e210-e211. | 2.2 | 3 |
| 76 | Cancer randomized trials showed that dissemination bias is still a problem to be solved. Journal of Clinical Epidemiology, 2016, 77, 84-90. | 2.4 | 4 |
| 77 | Eliciting regret improves decision making at the end of life. European Journal of Cancer, 2016, 68, 27-37. | 1.3 | 15 |
| 78 | Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents. JAMA Oncology, 2016, 2, 1499. | 3.4 | 6 |
| 79 | Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. Journal of Clinical Epidemiology, 2016, 80, 3-7. | 2.4 | 145 |
| 80 | When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members. BMJ Open, 2016, 6, e011150. | 0.8 | 2 |
| 81 | Activating clinical trials: a process improvement approach. Trials, 2016, 17, 106. | 0.7 | 8 |
| 82 | Reply. Hepatology, 2016, 63, 1051-1051. | 3.6 | 0 |
| 83 | World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 2016, 72, 98-106. | 2.4 | 58 |
| 84 | A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. Journal of Clinical Epidemiology, 2016, 70, 111-122. | 2.4 | 47 |
| 85 | GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE. Journal of Clinical Epidemiology, 2016, 75, 115-118. | 2.4 | 28 |
| 86 | Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. Journal of Clinical Epidemiology, 2016, 70, 123-128. | 2.4 | 16 |
| 87 | When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?. Blood, 2016, 128, 4007-4007. | 0.6 | 1 |
| 88 | Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients. Blood, 2016, 128, 3998-3998. | 0.6 | 0 |
| 89 | Improving Hospice Referral: Application of Regret-Based Decision Modeling at End-of-Life Care. Blood, 2016, 128, 535-535. | 0.6 | 0 |
| 90 | Rationality, practice variation and person-centred health policy: a threshold hypothesis. Journal of Evaluation in Clinical Practice, 2015, 21, 1121-1124. | 0.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Rough set theory based prognostic classification models for hospice referral. BMC Medical Informatics and Decision Making, 2015, 15, 98. | 1.5 | 8 |
| 92 | Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control, 2015, 22, 235-241. | 0.7 | 14 |
| 93 | Evidence-based medicine meets person-centred care: a collaborative perspective on the relationship. Journal of Evaluation in Clinical Practice, 2015, 21, 1047-1051. | 0.9 | 11 |
| 94 | Thinking Styles and Regret in Physicians. PLoS ONE, 2015, 10, e0134038. | 1.1 | 29 |
| 95 | When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology, 2015, 61, 905-914. | 3.6 | 69 |
| 96 | High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. Bone Marrow Transplantation, 2015, 50, 1069-1074. | 1.3 | 7 |
| 97 | Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation. Journal of Clinical Epidemiology, 2015, 68, 727-732. | 2.4 | 39 |
| 98 | Guideline panels should not GRADE good practice statements. Journal of Clinical Epidemiology, 2015, 68, 597-600. | 2.4 | 150 |
| 99 | Platelet Transfusion: A Clinical Practice Guideline From the AABB. Annals of Internal Medicine, 2015, 162, 205-213. | 2.0 | 717 |
| 100 | Modern health care as a game theory problem: reply. European Journal of Clinical Investigation, 2015, 45, 443-443. | 1.7 | 3 |
| 101 | When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation. European Journal of Clinical Investigation, 2015, 45, 485-493. | 1.7 | 50 |
| 102 | Value-Based Cancer Care and the Excessive Cost of Drugs. JAMA Oncology, 2015, 1, 1301. | 3.4 | 8 |
| 103 | Modern health care as a game theory problem. European Journal of Clinical Investigation, 2015, 45, 1-12. | 1.7 | 29 |
| 104 | Platelet transfusion: a systematic review of the clinical evidence. Transfusion, 2015, 55, 1116-1127. | 0.8 | 131 |
| 105 | Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67. | 1.1 | 16 |
| 106 | Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients. Blood, 2015, 126, 2505-2505. | 0.6 | 2 |
| 107 | Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing. PLoS ONE, 2015, 10, e0134800. | 1.1 | 16 |
| 108 | Those Responsible for Approving Research Studies Have Poor Knowledge of Research Study Design: a Knowledge Assessment of Institutional Review Board Members. Acta Informatica Medica, 2015, 23, 196. | 0.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435. | 2.3 | 55 |
| 110 | Evolution of Treatment Regimens in Multiple Myeloma: A Social Network Analysis. PLoS ONE, 2014, 9, e104555. | 1.1 | 5 |
| 111 | Indirect Treatment Comparison. The Stata Journal, 2014, 14, 76-86. | 0.9 | 26 |
| 112 | Human Judgment and Health Care Policy. Population Health Management, 2014, 17, 139-140. | 0.8 | 10 |
| 113 | Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: a protocol for a multinational structured interview-based study combined with a randomised survey on the optimal amount of information to elicit preferences. BMJ Open, 2014, 4, e005536. | 0.8 | 4 |
| 114 | From hospice to hospital: short-term follow-up study of hospice patient outcomes in a US acute care hospital surveillance system. BMJ Open, 2014, 4, e005196-e005196. | 0.8 | 6 |
| 115 | Benchmarks for detecting "breakthroughs" in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation. BMJ Open, 2014, 4, e005249. | 0.8 | 3 |
| 116 | Identifying homogenous subgroups for individual patient meta-analysis based on Rough Set Theory. , 2014, 2014, 3434-7. | | 1 |
| 117 | Improving the Drug Development Process. JAMA - Journal of the American Medical Association, 2014, 311, 355. | 3.8 | 23 |
| 118 | Evidence-Based Practice Is Not Synonymous With Delivery of Uniform Health Care. JAMA - Journal of the American Medical Association, 2014, 312, 1293. | 3.8 | 43 |
| 119 | A Framework to Bridge the Gaps Between Evidence-Based Medicine, Health Outcomes, and Improvement and Implementation Science. Journal of Oncology Practice, 2014, 10, 200-202. | 2.5 | 26 |
| 120 | Study Design and the Drug Development Process"Reply. JAMA - Journal of the American Medical Association, 2014, 311, 2023. | 3.8 | 0 |
| 121 | Evaluation of Physicians' Cognitive Styles. Medical Decision Making, 2014, 34, 627-637. | 1.2 | 32 |
| 122 | Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?. Genetics in Medicine, 2014, 16, 338-346. | 1.1 | 24 |
| 123 | How to increase value and reduce waste when research priorities are set. Lancet, The, 2014, 383, 156-165. | 6.3 | 1,102 |
| 124 | Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. The Cochrane Library, 2014, 2014, CD010280. | 1.5 | 33 |
| 125 | Concordance between decision analysis and matching systematic review of randomized controlled trials in assessment of treatment comparisons: a systematic review. BMC Medical Informatics and Decision Making, 2014, 14, 57. | 1.5 | 5 |
| 126 | Value of Repeat Head Computed Tomography after Traumatic Brain Injury: Systematic Review and Meta-Analysis. Journal of Neurotrauma, 2014, 31, 78-98. | 1.7 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | The EGAPP initiative: lessons learned. <i>Genetics in Medicine</i> , 2014, 16, 217-224. | 1.1 | 45 |
| 128 | How do physicians decide to treat: an empirical evaluation of the threshold model. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 47. | 1.5 | 42 |
| 129 | Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies. <i>Annals of Epidemiology</i> , 2014, 24, 734-740. | 0.9 | 4 |
| 130 | Treatment-related harms: What was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 354-356. | 2.4 | 4 |
| 131 | World Health Organization recommendations are often strong based on low confidence in effect estimates. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 629-634. | 2.4 | 62 |
| 132 | Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1677-1686. | 2.0 | 95 |
| 133 | Defining Optimum Treatment of Patients With Pancreatic Adenocarcinoma Using Regret-Based Decision Curve Analysis. <i>Annals of Surgery</i> , 2014, 259, 1208-1214. | 2.1 | 16 |
| 134 | Effect of Initial Conditions on Reproducibility of Scientific Research. <i>Acta Informatica Medica</i> , 2014, 22, 156. | 0.5 | 6 |
| 135 | Meta-Analysis Evaluating Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation As Front-Line Consolidation in Chronic Lymphocytic Leukemia: Results Do Not Justify This Treatment Approach. <i>Blood</i> , 2014, 124, 1306-1306. | 0.6 | 0 |
| 136 | Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2013, 2, 10. | 2.5 | 112 |
| 137 | Critical reflections on value in medicine. <i>Journal of Medicine and the Person</i> , 2013, 11, 69-72. | 0.1 | 3 |
| 138 | Trial unpredictability yields predictable therapy gains. <i>Nature</i> , 2013, 500, 395-396. | 13.7 | 54 |
| 139 | GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 726-735. | 2.4 | 950 |
| 140 | GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 158-172. | 2.4 | 618 |
| 141 | Sequence of novel agents in multiple myeloma: An instrumental variable analysis. <i>Leukemia Research</i> , 2013, 37, 1077-1082. | 0.4 | 1 |
| 142 | Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 654-659. | 2.4 | 34 |
| 143 | Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: A case study of meta-analyses of multiple myeloma trials. <i>Contemporary Clinical Trials</i> , 2013, 34, 257-261. | 0.8 | 9 |
| 144 | Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hematology and Oncology</i> , 2013, 6, 2. | 6.9 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy. <i>New England Journal of Medicine</i> , 2013, 368, 1131-1139. | 13.9 | 140 |
| 146 | Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. <i>Immunotherapy</i> , 2013, 5, 457-466. | 1.0 | 41 |
| 147 | Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis. <i>Cancer Treatment Reviews</i> , 2013, 39, 340-349. | 3.4 | 14 |
| 148 | Optimal type I and type II error pairs when the available sample size is fixed. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 903-910.e2. | 2.4 | 29 |
| 149 | Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes?. <i>Genetics in Medicine</i> , 2013, 15, 612-617. | 1.1 | 18 |
| 150 | Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. <i>Genetics in Medicine</i> , 2013, 15, 517-527. | 1.1 | 64 |
| 151 | Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. <i>Genetics in Medicine</i> , 2013, 15, 14-24. | 1.1 | 46 |
| 152 | Colony-Stimulating Factors for Febrile Neutropenia. <i>New England Journal of Medicine</i> , 2013, 369, 284-286. | 13.9 | 2 |
| 153 | Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?. <i>Leukemia Research and Treatment</i> , 2013, 2013, 1-4. | 2.0 | 8 |
| 154 | Comparator bias: why comparisons must address genuine uncertainties. <i>Journal of the Royal Society of Medicine</i> , 2013, 106, 30-33. | 1.1 | 29 |
| 155 | Adherence to antiretroviral therapy in India: A systematic review and meta-analysis. <i>Indian Journal of Community Medicine</i> , 2013, 38, 74. | 0.2 | 35 |
| 156 | Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2013, 163, 315-325. | 1.2 | 35 |
| 157 | Multiple Myeloma, Version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 11-17. | 2.3 | 63 |
| 158 | External validation of A Web-Based Prognostic Tool for Predicting Survival for Patients in Hospice Care. <i>Journal of Palliative Care</i> , 2013, 29, 140-146. | 0.4 | 3 |
| 159 | Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials. <i>PLoS ONE</i> , 2013, 8, e58711. | 1.1 | 32 |
| 160 | Trial Sequential Boundaries for Cumulative Meta-Analyses. <i>The Stata Journal</i> , 2013, 13, 77-91. | 0.9 | 48 |
| 161 | Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis. <i>Blood</i> , 2013, 122, 5372-5372. | 0.6 | 1 |
| 162 | At What Level of Collective Equipoise Does a Randomized Clinical Trial Become Ethical for the Members of Institutional Review Board/Ethical Committees?. <i>Acta Informatica Medica</i> , 2013, 21, 156. | 0.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Evaluation of spot urine protein to creatinine ratio and 24-hour urine protein quantification for proteinuria in patients with plasma cell dyscrasia.. Journal of Clinical Oncology, 2013, 31, e19516-e19516. | 0.8 | 0 |
| 164 | Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis. Blood, 2013, 122, 1945-1945. | 0.6 | 0 |
| 165 | A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia. Blood, 2013, 122, 3155-3155. | 0.6 | 0 |
| 166 | What does randomisation achieve?. Evidence-Based Medicine, 2012, 17, 1-2. | 0.6 | 11 |
| 167 | Towards a classification model to identify hospice candidates in terminally ill patients. , 2012, 2012, 1278-81. | | 1 |
| 168 | Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. Clinical Cancer Research, 2012, 18, 256-262. | 3.2 | 61 |
| 169 | New treatments compared to established treatments in randomized trials. The Cochrane Library, 2012, 10, MR000024. | 1.5 | 34 |
| 170 | Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 628-653. | 2.3 | 153 |
| 171 | Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1211-1219. | 2.3 | 38 |
| 172 | Bisphosphonates in multiple myeloma: a network meta-analysis. The Cochrane Library, 2012, , CD003188. | 1.5 | 74 |
| 173 | Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of Internal Medicine, 2012, 157, 49. | 2.0 | 920 |
| 174 | 67 ADVANCING COMPARATIVE EFFECTIVENESS RESEARCH THROUGH NETWORK META-ANALYSIS: INTRAVESICAL THERAPY IN BLADDER CANCER. Journal of Urology, 2012, 187, . | 0.2 | 0 |
| 175 | Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of Clinical Epidemiology, 2012, 65, 602-609. | 2.4 | 77 |
| 176 | Comparison of Mycophenolate Mofetil (MMF) Versus Methotrexate (MTX) for Prevention of Acute Graft-Versus-Host Disease: Results of a Meta-Analysis. Biology of Blood and Marrow Transplantation, 2012, 18, S358-S359. | 2.0 | 0 |
| 177 | Dual processing model of medical decision-making. BMC Medical Informatics and Decision Making, 2012, 12, 94. | 1.5 | 86 |
| 178 | Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia, 2012, 26, 582-588. | 3.3 | 65 |
| 179 | Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplantation, 2012, 47, 1164-1170. | 1.3 | 37 |
| 180 | When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC Medical Research Methodology, 2012, 12, 85. | 1.4 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | A Flexible Alternative to the Cox Proportional Hazards Model for Assessing the Prognostic Accuracy of Hospice Patient Survival. PLoS ONE, 2012, 7, e47804. | 1.1 | 16 |
| 182 | Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Propective Randomized Controlled Studies. Blood, 2012, 120, 4168-4168. | 0.6 | 6 |
| 183 | Maintenance Therapies for Multiple Myeloma (MM): A Network Meta-Analysis. Blood, 2012, 120, 236-236. | 0.6 | 0 |
| 184 | Comparative Efficacy of Tandem Autologous Versus Autologous Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2012, 120, 4519-4519. | 0.6 | 0 |
| 185 | Maintenance Therapies for Multiple Myeloma (MM): A Direct Meta-Analysis. Blood, 2012, 120, 4271-4271. | 0.6 | 0 |
| 186 | Social Network Analysis (SNA) of Salvage Therapies in Multiple Myeloma (MM). Blood, 2012, 120, 4239-4239. | 0.6 | 0 |
| 187 | Trial Sequential Analysis in Meta-Analyses of Maintenance Therapies for Multiple Myeloma.. Blood, 2012, 120, 2975-2975. | 0.6 | 0 |
| 188 | Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. The Cochrane Library, 2011, , CD008818. | 1.5 | 36 |
| 189 | Treatment of Patients with Multiple Myeloma: An Overview of Systematic Reviews. Acta Haematologica, 2011, 125, 8-22. | 0.7 | 27 |
| 190 | GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). Journal of Clinical Epidemiology, 2011, 64, 407-415. | 2.4 | 2,130 |
| 191 | Optimism bias leads to inconclusive results—an empirical study. Journal of Clinical Epidemiology, 2011, 64, 583-593. | 2.4 | 45 |
| 192 | GRADE guidelines: 5. Rating the quality of evidence—publication bias. Journal of Clinical Epidemiology, 2011, 64, 1277-1282. | 2.4 | 1,355 |
| 193 | Extensions to Regret-based Decision Curve Analysis: An application to hospice referral for terminal patients. BMC Medical Informatics and Decision Making, 2011, 11, 77. | 1.5 | 17 |
| 194 | Uncertainty in Clinical Medicine. , 2011, , 299-356. | | 42 |
| 195 | Uncertainty and Equipoise: At Interplay Between Epistemology, Decision Making and Ethics. American Journal of the Medical Sciences, 2011, 342, 282-289. | 0.4 | 22 |
| 196 | The Australian 'FORM' approach to guideline development: The quest for the perfect system. BMC Medical Research Methodology, 2011, 11, 17. | 1.4 | 6 |
| 197 | Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance. BMC Medical Research Methodology, 2011, 11, 55. | 1.4 | 6 |
| 198 | Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: A systematic review. American Journal of Hematology, 2011, 86, 18-24. | 2.0 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Rough Set Theory based prognostication of life expectancy for terminally ill patients. , 2011, 2011, 6438-41. | | 4 |
| 200 | Implications of the Principle of Question Propagation for Comparative-Effectiveness and "Data Mining" Research. JAMA - Journal of the American Medical Association, 2011, 305, 298. | 3.8 | 16 |
| 201 | Efficacy Research and Unanswered Clinical Questions"Reply. JAMA - Journal of the American Medical Association, 2011, 306, 709. | 3.8 | 1 |
| 202 | Designing patient-centric applications for chronic disease management. , 2011, 2011, 3146-9. | | 9 |
| 203 | From Efficacy to Effectiveness in the Face of Uncertainty. JAMA - Journal of the American Medical Association, 2011, 305, 2005-6. | 3.8 | 88 |
| 204 | Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical Trials, 2011, 8, 591-600. | 0.7 | 20 |
| 205 | Social Network Analysis (SNA) of Research Programs In Multiple Myeloma (MM). Blood, 2011, 118, 3144-3144. | 0.6 | 1 |
| 206 | Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5142-5142. | 0.6 | 1 |
| 207 | A Social Network Analysis of Treatment Discoveries in Cancer. PLoS ONE, 2011, 6, e18060. | 1.1 | 4 |
| 208 | Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment Related Harms Reporting: An Analysis of National Cancer Institute's Co-Operative Group Phase III Randomized Controlled Trials. Blood, 2011, 118, 673-673. | 0.6 | 0 |
| 209 | Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials. Blood, 2011, 118, 508-508. | 0.6 | 0 |
| 210 | External Validation of Prognostic Models in Terminally Ill Patients,. Blood, 2011, 118, 4186-4186. | 0.6 | 0 |
| 211 | Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis. Blood, 2011, 118, 1878-1878. | 0.6 | 1 |
| 212 | Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,. Blood, 2011, 118, 3979-3979. | 0.6 | 9 |
| 213 | Bisphosphonates in multiple myeloma. , 2010, , CD003188. | | 27 |
| 214 | Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica, 2010, 95, 340-342. | 1.7 | 29 |
| 215 | Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Research and Treatment, 2010, 121, 771-776. | 1.1 | 2 |
| 216 | A regret theory approach to decision curve analysis: A novel method for eliciting decision makers' preferences and decision-making. BMC Medical Informatics and Decision Making, 2010, 10, 51. | 1.5 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Evidence-based practice guidelines for plasma transfusion. <i>Transfusion</i> , 2010, 50, 1227-1239. | 0.8 | 269 |
| 218 | Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects_{title}>Systematic Review and Meta-regression Analysis</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1180. | 3.8 | 524 |
| 219 | Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. <i>Clinical Trials</i> , 2010, 7, 312-321. | 0.7 | 87 |
| 220 | Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 341, c4543-c4543. | 2.4 | 257 |
| 221 | Timing of first-line cancer treatments – Early versus late – A systematic review of phase III randomized trials. <i>Cancer Treatment Reviews</i> , 2010, 36, 621-628. | 3.4 | 12 |
| 222 | Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis.. <i>Blood</i> , 2010, 116, 1513-1513. | 0.6 | 1 |
| 223 | Role of Iron Supplementation to Erythropoiesis Stimulating Agents In the Management of Chemotherapy-Induced Anemia In Cancer Patients: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2010, 116, 2055-2055. | 0.6 | 6 |
| 224 | Comparative Effectiveness of Bisphosphonates In Multiple Myeloma. <i>Blood</i> , 2010, 116, 3028-3028. | 0.6 | 2 |
| 225 | JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. <i>PLoS ONE</i> , 2010, 5, e13591. | 1.1 | 6 |
| 226 | Comparative Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 3995-3995. | 0.6 | 0 |
| 227 | Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia In First Complete Remission: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2010, 116, 3511-3511. | 0.6 | 0 |
| 228 | Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. <i>The Journal of Supportive Oncology</i> , 2010, 8, 84-91. | 2.3 | 2 |
| 229 | The Paradox of Equipoise: The Principle that Drives and Limits Therapeutic Discoveries in Clinical Research. <i>Cancer Control</i> , 2009, 16, 342-347. | 0.7 | 48 |
| 230 | Risk Prediction Versus Diagnosis: Preserving Clinical Nuance in a Binary World. <i>Annals of Internal Medicine</i> , 2009, 150, 223. | 2.0 | 0 |
| 231 | Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043. | 0.8 | 132 |
| 232 | Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. <i>Annals of Oncology</i> , 2009, 20, 520-525. | 0.6 | 302 |
| 233 | Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2349. | 3.8 | 758 |
| 234 | Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. <i>The Cochrane Library</i> , 2009, , CD007303. | 1.5 | 98 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2009, 101, 100-106. | 3.0 | 97 |
| 236 | Response: Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2009, 101, 966-967. | 3.0 | 5 |
| 237 | Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2009, 15, 3850-3855. | 3.2 | 25 |
| 238 | Impact of quality of evidence on the strength of recommendations: an empirical study. <i>BMC Health Services Research</i> , 2009, 9, 120. | 0.9 | 35 |
| 239 | Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). <i>Trials</i> , 2009, 10, 49. | 0.7 | 28 |
| 240 | Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 893-902. | 2.0 | 41 |
| 241 | Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1005-1013. | 2.0 | 116 |
| 242 | Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1415-1421. | 2.0 | 70 |
| 243 | Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2009, 373, 1532-1542. | 6.3 | 546 |
| 244 | SYSTEMATIC REVIEWS FOR PROSTATE CANCER: OVERWHELMING TASK FOR CLINICIANS. <i>Journal of Urology</i> , 2009, 181, 6-6. | 0.2 | 0 |
| 245 | Epistemologic Inquiries in Evidence-Based Medicine. <i>Cancer Control</i> , 2009, 16, 158-168. | 0.7 | 164 |
| 246 | Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 908-942. | 2.3 | 112 |
| 247 | Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis.. <i>Blood</i> , 2009, 114, 3858-3858. | 0.6 | 1 |
| 248 | Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations. <i>Seminars in Hematology</i> , 2008, 45, 167-175. | 1.8 | 17 |
| 249 | Decision-Making When Data and Inferences Are Not Conclusive: Risk-Benefit and Acceptable Regret Approach. <i>Seminars in Hematology</i> , 2008, 45, 150-159. | 1.8 | 26 |
| 250 | Multiple myeloma: detecting the effects of new treatments. <i>Lancet, The</i> , 2008, 371, 1642-1644. | 6.3 | 10 |
| 251 | Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2008, 26, 132-149. | 0.8 | 274 |
| 252 | Recommendations on the Use of ¹⁸ F-FDG PET in Oncology. <i>Journal of Nuclear Medicine</i> , 2008, 49, 480-508. | 2.8 | 978 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach. <i>Medical Decision Making</i> , 2008, 28, 540-553. | 1.2 | 57 |
| 254 | Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 914. | 3.8 | 657 |
| 255 | Randomized Trials in Oncology Stopped Early for Benefit. <i>Journal of Clinical Oncology</i> , 2008, 26, 18-19. | 0.8 | 44 |
| 256 | Treatment Success in Cancer_{title}New Cancer Treatment Successes Identified in Phase 3 Randomized Controlled Trials Conducted by the National Cancer Instituteâ€“Sponsored Cooperative Oncology Groups, 1955 to 2006</sub>. <i>Archives of Internal Medicine</i> , 2008, 168, 632. | 4.3 | 94 |
| 257 | Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. <i>Blood</i> , 2008, 111, 25-41. | 0.6 | 130 |
| 258 | A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma. <i>Blood</i> , 2008, 112, 236-236. | 0.6 | 9 |
| 259 | Efficacy of Hypo-Methylating Agents in the Treatment of Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Blood</i> , 2008, 112, 3632-3632. | 0.6 | 4 |
| 260 | Cancer- and Chemotherapy-Induced Anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 536. | 2.3 | 86 |
| 261 | Hodgkin Disease/Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 594. | 2.3 | 9 |
| 262 | Thalidomide Versus Bortezomib-Based Regimens for Relapsed Myeloma: Meta-Analysis and Indirect Meta-Analysis. <i>Blood</i> , 2008, 112, 2362-2362. | 0.6 | 0 |
| 263 | Expectation Bias-the Main Culprit for Large Number of Inconclusive Randomized Controlled Trials in Hematological Malignancies. <i>Blood</i> , 2008, 112, 671-671. | 0.6 | 1 |
| 264 | When Should Potentially False Research Findings Be Considered Acceptable?. <i>PLoS Medicine</i> , 2007, 4, e26. | 3.9 | 55 |
| 265 | Treatment Tolerance and Efficacy in Geriatric Oncology: A Systematic Review of Phase III Randomized Trials Conducted by Five National Cancer Instituteâ€“Sponsored Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2007, 25, 1272-1276. | 0.8 | 101 |
| 266 | Evaluation of Serious Adverse Drug Reactions. <i>Archives of Internal Medicine</i> , 2007, 167, 1041. | 4.3 | 43 |
| 267 | The Sound and the Fury: Financial Conflicts of Interest in Oncology. <i>Journal of Clinical Oncology</i> , 2007, 25, 3567-3569. | 0.8 | 12 |
| 268 | Articulating and Responding to Uncertainties in Clinical Research. <i>Journal of Medicine and Philosophy</i> , 2007, 32, 79-98. | 0.4 | 65 |
| 269 | Evidence-Based Medicine for Rare Diseases: Implications for Data Interpretation and Clinical Trial Design. <i>Cancer Control</i> , 2007, 14, 160-166. | 0.7 | 48 |
| 270 | A Systematic Review of Quality of Life Associated with Standard Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1091-1097. | 0.5 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 183-196. | 2.0 | 216 |
| 272 | Evidence profiles for breast cancer: Benefit/harms data based on the totality of randomized evidence. <i>Cancer Treatment Reviews</i> , 2007, 33, 87-89. | 3.4 | 3 |
| 273 | Systematic Review of Piperacillin-Induced Neutropenia. <i>Drug Safety</i> , 2007, 30, 295-306. | 1.4 | 44 |
| 274 | Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?. <i>British Journal of Haematology</i> , 2007, 139, 234-242. | 1.2 | 8 |
| 275 | Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study.. <i>Blood</i> , 2007, 110, 125-125. | 0.6 | 17 |
| 276 | Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).. <i>Blood</i> , 2007, 110, 5131-5131. | 0.6 | 1 |
| 277 | Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).. <i>Blood</i> , 2007, 110, 936-936. | 0.6 | 3 |
| 278 | Multiple Myeloma Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 118. | 2.3 | 43 |
| 279 | Estimating Net Benefits and Harms of Screening Mammography in Women Age 40 to 49 Years. <i>Annals of Internal Medicine</i> , 2007, 147, 882. | 2.0 | 1 |
| 280 | Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.. <i>Blood</i> , 2007, 110, 3340-3340. | 0.6 | 0 |
| 281 | Treatment Success in Cancer.. <i>Blood</i> , 2007, 110, 631-631. | 0.6 | 0 |
| 282 | Role of High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review and Meta-Analysis.. <i>Blood</i> , 2007, 110, 2872-2872. | 0.6 | 3 |
| 283 | Are systematic reviews more cost-effective than randomised trials?. <i>Lancet, The</i> , 2006, 367, 2057-2058. | 6.3 | 21 |
| 284 | Screening mammography at 40â€“49 years: regret or no regret?. <i>Lancet, The</i> , 2006, 368, 2035-2037. | 6.3 | 134 |
| 285 | Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients. <i>Journal of the National Cancer Institute</i> , 2006, 98, 708-714. | 3.0 | 510 |
| 286 | High-quality evidence in oncology from 16 June to 18 August 2005: A summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 59-64. | 3.4 | 0 |
| 287 | High-quality evidence in oncology from 25 August to 27 October 2005: A summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 149-155. | 3.4 | 0 |
| 288 | High-quality evidence in oncology from 3 November to 24 November, 2005: A summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 239-241. | 3.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | High-quality evidence in oncology from 1 December to 22 December 2005: a summary. <i>Cancer Treatment Reviews</i> , 2006, 32, 402-405. | 3.4 | 0 |
| 290 | Cancer treatment reviews welcomes submission of the Cochrane Reviews. <i>Cancer Treatment Reviews</i> , 2006, 32, 243-244. | 3.4 | 1 |
| 291 | Evidence profiles for colo-rectal cancer: Benefit/harms data based on the totality of randomized evidence. <i>Cancer Treatment Reviews</i> , 2006, 32, 577-580. | 3.4 | 0 |
| 292 | What kind of evidence do patients and practitioners need: Evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. <i>Cancer Treatment Reviews</i> , 2006, 32, 572-576. | 3.4 | 13 |
| 293 | Evidence profiles for lung cancer: Benefit/harms data based on the totality of randomized evidence. <i>Cancer Treatment Reviews</i> , 2006, 32, 652-655. | 3.4 | 0 |
| 294 | Erythropoietin or Darbepoetin for patients with cancer. , 2006, , CD003407. | | 106 |
| 295 | In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. <i>British Journal of Haematology</i> , 2006, 132, 656-658. | 1.2 | 16 |
| 296 | Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. <i>Journal of Evaluation in Clinical Practice</i> 12, 248-256. <i>Journal of Evaluation in Clinical Practice</i> , 2006, 12, 257-259. | 0.9 | 18 |
| 297 | Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4867-4874. | 0.8 | 675 |
| 298 | Plasmapheresis in the Treatment of Renal Failure Associated with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3585-3585. | 0.6 | 2 |
| 299 | Role of High-Dose Chemotherapy with Autologous Haematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin's Disease.. <i>Blood</i> , 2006, 108, 5432-5432. | 0.6 | 0 |
| 300 | Evaluation of New Treatments in Radiation Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 970. | 3.8 | 78 |
| 301 | Estimating the mean and variance from the median, range, and the size of a sample. <i>BMC Medical Research Methodology</i> , 2005, 5, 13. | 1.4 | 6,548 |
| 302 | Use of re-randomized data in meta-analysis. <i>BMC Medical Research Methodology</i> , 2005, 5, 17. | 1.4 | 15 |
| 303 | Acting on Imperfect Evidence: How Much Regret Are We Ready to Accept?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6822-6825. | 0.8 | 27 |
| 304 | Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. <i>BMJ: British Medical Journal</i> , 2005, 331, 1295. | 2.4 | 58 |
| 305 | Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 4198-4214. | 0.8 | 273 |
| 306 | High-quality evidence in oncology from 22nd June to 26th August 2004: a summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 63-67. | 3.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | High-quality evidence in oncology from 1st September to 14th October 2004: a summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 155-157. | 3.4 | 0 |
| 308 | Oncology treatment recommendations can be supported only by 2% of high-quality published evidence. <i>Cancer Treatment Reviews</i> , 2005, 31, 319-322. | 3.4 | 18 |
| 309 | The challenge of systematic reviews of diagnostic and staging studies in cancer. <i>Cancer Treatment Reviews</i> , 2005, 31, 628-639. | 3.4 | 10 |
| 310 | High-quality evidence in oncology from 14 April to 12 May 2005: A summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 587-589. | 3.4 | 0 |
| 311 | High-quality evidence in oncology from 19 May to 9 June 2005: A summary. <i>Cancer Treatment Reviews</i> , 2005, 31, 653-656. | 3.4 | 0 |
| 312 | Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 455-466. | 0.7 | 17 |
| 313 | Quality of Reporting of Harms in the NCI Sponsored Phase III Hematological Malignancies Trials.. <i>Blood</i> , 2005, 106, 292-292. | 0.6 | 0 |
| 314 | Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results.. <i>Blood</i> , 2005, 106, 751-751. | 0.6 | 2 |
| 315 | Are Statistically Non-Significant Findings Necessarily Negative? A Review of All Phase III Randomized Controlled Trials in Hematology Conducted by NCI Sponsored Cooperative Groups.. <i>Blood</i> , 2005, 106, 293-293. | 0.6 | 1 |
| 316 | Citation Impact of Breakthrough Interventions for Malignant Blood Disorders.. <i>Blood</i> , 2005, 106, 3115-3115. | 0.6 | 0 |
| 317 | Relationship of Harvest CD34+ and CD3+ Counts To Chronic Graft-Versus-Host Disease (cGVHD), Relapse and Survival Following Sibling Allogeneic Stem Cell Transplant.. <i>Blood</i> , 2005, 106, 1820-1820. | 0.6 | 0 |
| 318 | Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. <i>BMJ: British Medical Journal</i> , 2004, 328, 22-24. | 2.4 | 263 |
| 319 | Lifting the fog of uncertainty from the practice of medicine. <i>BMJ: British Medical Journal</i> , 2004, 329, 1419-1420. | 2.4 | 29 |
| 320 | Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2004, 5, 285-285. | 2.0 | 4 |
| 321 | High-quality evidence in oncology from 20th April to 11th May 2004: a summary. <i>Cancer Treatment Reviews</i> , 2004, 30, 665-667. | 3.4 | 1 |
| 322 | High-quality evidence in oncology from 18th May to 15th June 2004: a summary. <i>Cancer Treatment Reviews</i> , 2004, 30, 721-723. | 3.4 | 0 |
| 323 | Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. <i>Blood</i> , 2004, 103, 3271-3277. | 0.6 | 163 |
| 324 | Well informed uncertainties about the effects of treatment. <i>BMJ: British Medical Journal</i> , 2004, 328, 1018.2. | 2.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Systematic Review and Meta-Analysis of Randomized Controlled Trials of Erythropoietin in Multiple Myeloma.. Blood, 2004, 104, 232-232. | 0.6 | 2 |
| 326 | Detection of Cytokeratin-19 in Peripheral Blood of Breast Cancer Patients: Results from a Systematic Review/Meta-Analysis.. Blood, 2004, 104, 5314-5314. | 0.6 | 0 |
| 327 | Clinical Equipoise and the Therapeutic Misconception. Hastings Center Report, 2003, 33, 4. | 0.7 | 3 |
| 328 | Choosing a control intervention for a randomised clinical trial. BMC Medical Research Methodology, 2003, 3, 7. | 1.4 | 43 |
| 329 | Letter to the Editor. Journal of Law, Medicine and Ethics, 2003, 31, 5-6. | 0.4 | 4 |
| 330 | Off-study availability of investigational treatments. Lancet, The, 2003, 361, 1302. | 6.3 | 1 |
| 331 | Evidence-based Oncology section " aims and scope. Cancer Treatment Reviews, 2003, 29, 51-53. | 3.4 | 0 |
| 332 | Evidence-based oncology in cancer treatment reviews. Cancer Treatment Reviews, 2003, 29, 45-50. | 3.4 | 3 |
| 333 | Evidence-based Oncology section " policies and scope. Cancer Treatment Reviews, 2003, 29, 121-122. | 3.4 | 1 |
| 334 | Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncology, The, 2003, 4, 293-304. | 5.1 | 100 |
| 335 | The Importance of the Preservation of the Ethical Principle of Equipoise in the Design of Clinical Trials: Relative Impact of the Methodological Quality Domains on the Treatment Effect in Randomized Controlled Trials. Accountability in Research, 2003, 10, 301-315. | 1.6 | 35 |
| 336 | Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients. Journal of Clinical Oncology, 2003, 21, 4615-4626. | 0.8 | 263 |
| 337 | Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ: British Medical Journal, 2003, 326, 1167-1170. | 2.4 | 1,733 |
| 338 | Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-398. | 2.0 | 374 |
| 339 | A Systematic Review and Lessons Learned from Early Lung Cancer Detection Trials Using Low-Dose Computed Tomography of the Chest. Cancer Control, 2003, 10, 306-314. | 0.7 | 49 |
| 340 | Nonmyeloablative Allogeneic Stem-Cell Transplantation for Hematologic Malignancies: A Systematic Review. Cancer Control, 2003, 10, 17-41. | 0.7 | 24 |
| 341 | High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica, 2003, 88, 1304-15. | 1.7 | 53 |
| 342 | Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2003, 4, 379-98. | 2.0 | 86 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Clinical equipoise and the therapeutic misconception. Hastings Center Report, 2003, 33, 4; author reply 4-5. | 0.7 | 2 |
| 344 | Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of Clinical Oncology, 2002, 20, 4083-4107. | 0.8 | 393 |
| 345 | Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 2002, 100, 2303-2320. | 0.6 | 196 |
| 346 | Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. American Journal of Medicine, 2002, 112, 406-411. | 0.6 | 216 |
| 347 | Overlooking patient outcomes in a meta-analysis of trials of granulocyte colon-stimulating factor. American Journal of Medicine, 2002, 113, 766-768. | 0.6 | 0 |
| 348 | Bisphosphonates in multiple myeloma. , 2002, , CD003188. | | 69 |
| 349 | Priority-setting decisions for new cancer drugs. Lancet, The, 2002, 359, 1525. | 6.3 | 1 |
| 350 | Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncology, The, 2002, 3, 145-153. | 5.1 | 51 |
| 351 | Erythropoietin improves quality of life—a response. Lancet Oncology, The, 2002, 3, 527. | 5.1 | 3 |
| 352 | Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer, 2002, 2, 23. | 1.1 | 38 |
| 353 | Quality and methods of developing practice guidelines. BMC Health Services Research, 2002, 2, 1. | 0.9 | 63 |
| 354 | At what degree of belief in a research hypothesis is a trial in humans justified?. Journal of Evaluation in Clinical Practice, 2002, 8, 269-276. | 0.9 | 14 |
| 355 | A data-mining approach to improving Polycythemia Vera diagnosis. Computers and Industrial Engineering, 2002, 43, 765-773. | 3.4 | 16 |
| 356 | Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ, The, 2002, 325, 1420; author reply 1420. | 3.0 | 3 |
| 357 | Is clinical research still too haphazard?. Lancet, The, 2001, 358, 1648. | 6.3 | 11 |
| 358 | Placebo-Controlled Trials. Annals of Internal Medicine, 2001, 135, 62. | 2.0 | 11 |
| 359 | Evaluation and appraisal of randomized controlled trials in myeloma. Annals of Oncology, 2001, 12, 1611-1617. | 0.6 | 11 |
| 360 | The natural history of refractory idiopathic thrombocytopenic purpura. Blood, 2001, 98, 2282-2283. | 0.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Acknowledgment of uncertainty: A fundamental means to ensure scientific and ethical validity in clinical research. <i>Current Oncology Reports</i> , 2001, 3, 389-395. | 1.8 | 56 |
| 362 | Scientific and Ethical Issues in Equivalence Trials. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 1206. | 3.8 | 67 |
| 363 | Informing Patients of Uncertainty in Clinical Trials—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 2713. | 3.8 | 3 |
| 364 | A clinical score identified cancer patients with febrile neutropenia at low risk for complications. <i>ACP Journal Club</i> , 2001, 134, 76. | 0.1 | 0 |
| 365 | Evidentiary challenges to evidence-based medicine. <i>Journal of Evaluation in Clinical Practice</i> , 2000, 6, 99-109. | 0.9 | 40 |
| 366 | Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. <i>Annals of Oncology</i> , 2000, 11, 1591-1595. | 0.6 | 38 |
| 367 | The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts. <i>Archives of Internal Medicine</i> , 2000, 160, 1630. | 4.3 | 343 |
| 368 | Industry-sponsored research. <i>Lancet, The</i> , 2000, 356, 2194. | 6.3 | 1 |
| 369 | Acquired anaemias and polycythaemia. <i>Lancet, The</i> , 2000, 356, 596. | 6.3 | 0 |
| 370 | The uncertainty principle and industry-sponsored research. <i>Lancet, The</i> , 2000, 356, 635-638. | 6.3 | 442 |
| 371 | Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2000, , CD003039. | | 19 |
| 372 | Talking about Treatment. <i>Annals of Internal Medicine</i> , 2000, 132, 94. | 2.0 | 1 |
| 373 | A Young Man with Lymphocytosis. <i>Cancer Control</i> , 1999, 6, 1-5. | 0.7 | 0 |
| 374 | Using the Internet to Calculate Clinical Action Thresholds. <i>Journal of Biomedical Informatics</i> , 1999, 32, 168-185. | 0.7 | 11 |
| 375 | Acceptable regret in medical decision making. <i>Medical Hypotheses</i> , 1999, 53, 253-259. | 0.8 | 66 |
| 376 | The quality of medical evidence in hematology-oncology. <i>American Journal of Medicine</i> , 1999, 106, 198-205. | 0.6 | 48 |
| 377 | High-Dose Chemotherapy in the Adjuvant Treatment of Breast Cancer: Benefit/Risk Analysis. <i>Cancer Control</i> , 1998, 5, 394-405. | 0.7 | 22 |
| 378 | Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. , 1996, 51, 168-170. | | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 379 | Equation and Nomogram for Calculation of Testing and Treatment Thresholds. <i>Medical Decision Making</i> , 1996, 16, 198-199. | 1.2 | 14 |
| 380 | Comparison of the quality of life between HIV-positive haemophilia patients and HIV-negative haemophilia patients. <i>Haemophilia</i> , 1996, 2, 166-172. | 1.0 | 24 |
| 381 | Concomitant Treatment with Factor IX Concentrates and Antifibrinolytics in Hemophilia B. <i>Acta Haematologica</i> , 1995, 94, 43-48. | 0.7 | 7 |
| 382 | Lack of prophylactic anticoagulant therapy is not associated with clinical thrombotic complications in patients with hemophilia who undergo orthopedic surgical procedures. <i>American Journal of Hematology</i> , 1995, 50, 229-230. | 2.0 | 4 |
| 383 | Diagnostic entropy as a function of therapeutic benefit/risk ratio. <i>Medical Hypotheses</i> , 1995, 45, 503-509. | 0.8 | 3 |
| 384 | HLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome. <i>American Journal of Hematology</i> , 1994, 47, 189-193. | 2.0 | 24 |
| 385 | An Estimation of Life Expectancy: The Method Is a Message. <i>Medical Decision Making</i> , 1993, 13, 245-246. | 1.2 | 4 |
| 386 | High-Dose Chlorambucil and Dexamethasone for Relapsed Non-Hodgkin's Lymphomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 319-322. | 0.6 | 6 |
| 387 | Residual mediastinal mass after treatment of Hodgkin's disease: A decision analysis. <i>Medical Hypotheses</i> , 1992, 38, 166-175. | 0.8 | 7 |
| 388 | Disseminated Intravascular Coagulation after Factor IX Complex Resolved Using Purified Factor IX Concentrate. <i>Annals of Internal Medicine</i> , 1991, 115, 621. | 2.0 | 7 |
| 389 | Occurrence of high-grade T-Cell lymphoma in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: Case report and review of the literature. <i>American Journal of Hematology</i> , 1991, 36, 63-64. | 2.0 | 15 |
| 390 | Comparison of Different Treatment strategies for Diffuse Large-cell Lymphomas. <i>Medical Decision Making</i> , 1991, 11, 1-8. | 1.2 | 8 |
| 391 | Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 430-436. | 0.9 | 29 |
| 392 | A new algorithm for diagnosis of anemia. <i>Postgraduate Medicine</i> , 1989, 85, 119-130. | 0.9 | 6 |
| 393 | Differentiated HL-60 promyelocytic leukaemia cells produce a factor inducing differentiation. <i>Leukemia Research</i> , 1987, 11, 259-264. | 0.4 | 5 |
| 394 | Mathematical Model of Acute Myeloblastic Leukaemia: an Investigation of the Relevant Kinetic Parameters. <i>Cell Proliferation</i> , 1985, 18, 307-319. | 2.4 | 13 |
| 395 | Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. <i>The Cochrane Library</i> , 0, , . | 1.5 | 0 |
| 396 | Chemoprevention agents for prostate cancer. <i>The Cochrane Library</i> , 0, , . | 1.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|----|-----------|
| 397 | The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies. , 0 , 402-411. | | 0 |